Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lambert-Eaton Myasthenic Syndrome × Amifampridine × 1 year × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Conditions

Nystagmus, Pathologic 1 Myasthenic Syndromes, Congenital 1 Lambert-Eaton Myasthenic Syndrome 1

Interventions

thymoglobulin 1 prednylidene 1 deltacortene 1 carmustine, poliferprosan 20 drug combination 1 Walk Test 1 Prednisone 1 Physical Therapy Modalities 1 Peripheral Blood Stem Cell Transplantation 1 Melphalan 1 Etoposide 1 Cytarabine 1 Carmustine 1 Antilymphocyte Serum 1 Amifampridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02189720 2025-03-26

EAP-001

Catalyst Pharmaceuticals, Inc.

Approved for marketing

Nystagmus, Pathologic, Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

Data powered by HemOnc (CC BY 4.0) Colophon ⚡